Pharmacologic actions of 4-aminoquinoline compounds
Identifieur interne : 003658 ( Main/Exploration ); précédent : 003657; suivant : 003659Pharmacologic actions of 4-aminoquinoline compounds
Auteurs : Allen H. Mackenzie [États-Unis]Source :
- The American Journal of Medicine [ 0002-9343 ] ; 1983.
English descriptors
- Teeft :
- Acid hydrolases, American journal, Antimalarial, Antimalarial drugs, Arthritis, Arthritis rheum, Autophagic vacuoles, Biochem pharmacol, Cell biol, Cell surface, Cell surface receptors, Chloroquine, Chloroquine phosphate, Ciliary body, Cleveland clinic foundation, Clin, Concentration range, Dosage regimens, Early sign, Epithelium, Excessive dosage, Further studies, Higher concentrations, Human fibroblasts, Hydroxychloroquine, Hydroxychloroquine sulfate, Immunologic disease, Lysosomal, Lysosomal actions, Lysosomal function, Lysosomal storage disease, Lysosome, Macrophage, Pharmacologic actions, Plaquenil, Plasma membrane, Proc natl acad, Receptor, Retinal, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatologic effectiveness, Serum concentration, Serum levels, Side chain, Systemic lupus erythematosus, Toxicity, Vesicle, Vesicle fusion.
Abstract
Abstract: The pharmacokinetics, physiologic effects, and the metabolization of chloroquine and hydroxychloroquine are all similar. Their concentrations in plasma and tissue are directly related to daily dosing. The highest concentrations are found in melanin-containing tissues, particularly the choroid and ciliary body of the eye. The pharmacologic effects of 4-aminoquinoline compounds are reviewed in detail. It is likely that the rheumatologic effectiveness of these agents is primarily related to lysosomal actions. The drug-induced lysosomal abnormalities include diminished vesicle fusion, diminished exocytosis, and reversible “lysosomal storage disease.” It is likely that the retinal toxicity of these drugs is one manifestation of the altered lysosomal physiology involving the retinal pigmented epithelium. Tissue of retinal pigmented epithelium is similar to that of the bone-marrow-derived macrophage. Depression of extra-oculogram is an early sign of excessive dosage and can be used to measure potential toxicity during therapy with 4-aminoquinolines. Dosages ranging from 3.5 to 4.0 mg/kg per day for chloroquine and 6.0 to 6.5 mg/kg per day for hydroxychloroquine are clinically safe.
Url:
DOI: 10.1016/0002-9343(83)91264-0
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000018
- to stream Istex, to step Curation: 000018
- to stream Istex, to step Checkpoint: 002418
- to stream Main, to step Merge: 003735
- to stream Main, to step Curation: 003658
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacologic actions of 4-aminoquinoline compounds</title><author><name sortKey="Mackenzie, Allen H" sort="Mackenzie, Allen H" uniqKey="Mackenzie A" first="Allen H." last="Mackenzie">Allen H. Mackenzie</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D5E8C31BA7999187B9DB886DF26381C86BDE3503</idno><date when="1983" year="1983">1983</date><idno type="doi">10.1016/0002-9343(83)91264-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-QJ3RBWS1-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000018</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000018</idno><idno type="wicri:Area/Istex/Curation">000018</idno><idno type="wicri:Area/Istex/Checkpoint">002418</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002418</idno><idno type="wicri:doubleKey">0002-9343:1983:Mackenzie A:pharmacologic:actions:of</idno><idno type="wicri:Area/Main/Merge">003735</idno><idno type="wicri:Area/Main/Curation">003658</idno><idno type="wicri:Area/Main/Exploration">003658</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pharmacologic actions of 4-aminoquinoline compounds</title><author><name sortKey="Mackenzie, Allen H" sort="Mackenzie, Allen H" uniqKey="Mackenzie A" first="Allen H." last="Mackenzie">Allen H. Mackenzie</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cleveland, Ohio</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">The American Journal of Medicine</title><title level="j" type="abbrev">AJM</title><idno type="ISSN">0002-9343</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1983">1983</date><biblScope unit="volume">75</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="supplement">P1</biblScope><biblScope unit="page" from="5">5</biblScope><biblScope unit="page" to="10">10</biblScope></imprint><idno type="ISSN">0002-9343</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-9343</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acid hydrolases</term><term>American journal</term><term>Antimalarial</term><term>Antimalarial drugs</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autophagic vacuoles</term><term>Biochem pharmacol</term><term>Cell biol</term><term>Cell surface</term><term>Cell surface receptors</term><term>Chloroquine</term><term>Chloroquine phosphate</term><term>Ciliary body</term><term>Cleveland clinic foundation</term><term>Clin</term><term>Concentration range</term><term>Dosage regimens</term><term>Early sign</term><term>Epithelium</term><term>Excessive dosage</term><term>Further studies</term><term>Higher concentrations</term><term>Human fibroblasts</term><term>Hydroxychloroquine</term><term>Hydroxychloroquine sulfate</term><term>Immunologic disease</term><term>Lysosomal</term><term>Lysosomal actions</term><term>Lysosomal function</term><term>Lysosomal storage disease</term><term>Lysosome</term><term>Macrophage</term><term>Pharmacologic actions</term><term>Plaquenil</term><term>Plasma membrane</term><term>Proc natl acad</term><term>Receptor</term><term>Retinal</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatologic effectiveness</term><term>Serum concentration</term><term>Serum levels</term><term>Side chain</term><term>Systemic lupus erythematosus</term><term>Toxicity</term><term>Vesicle</term><term>Vesicle fusion</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The pharmacokinetics, physiologic effects, and the metabolization of chloroquine and hydroxychloroquine are all similar. Their concentrations in plasma and tissue are directly related to daily dosing. The highest concentrations are found in melanin-containing tissues, particularly the choroid and ciliary body of the eye. The pharmacologic effects of 4-aminoquinoline compounds are reviewed in detail. It is likely that the rheumatologic effectiveness of these agents is primarily related to lysosomal actions. The drug-induced lysosomal abnormalities include diminished vesicle fusion, diminished exocytosis, and reversible “lysosomal storage disease.” It is likely that the retinal toxicity of these drugs is one manifestation of the altered lysosomal physiology involving the retinal pigmented epithelium. Tissue of retinal pigmented epithelium is similar to that of the bone-marrow-derived macrophage. Depression of extra-oculogram is an early sign of excessive dosage and can be used to measure potential toxicity during therapy with 4-aminoquinolines. Dosages ranging from 3.5 to 4.0 mg/kg per day for chloroquine and 6.0 to 6.5 mg/kg per day for hydroxychloroquine are clinically safe.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Ohio</li></region></list><tree><country name="États-Unis"><region name="Ohio"><name sortKey="Mackenzie, Allen H" sort="Mackenzie, Allen H" uniqKey="Mackenzie A" first="Allen H." last="Mackenzie">Allen H. Mackenzie</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003658 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003658 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D5E8C31BA7999187B9DB886DF26381C86BDE3503
|texte= Pharmacologic actions of 4-aminoquinoline compounds
}}
| This area was generated with Dilib version V0.6.33. |  |